American Society of Clinical Oncology Choosing Wisely; Last Reviewed 2021 ASCO's 2021 Top Five List in Oncology The American Society of Clinical Oncology (ASCO) is a medical professional oncology ...

The YIA is a one-year grant totaling $50,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants & Awards Ceremony at the ASCO Annual Meeting. Applicants ...

Panel Question and Answer - ASCO ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte ...

The 2026 cycle opens July 1, 2025. All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. - ASCO ...

Diagnostic accuracy of machine learning models in glioma classification: A meta-analysis. - ASCO ...

Decentralized clinical trial elements can be safely adopted as permanent fixtures without substantial reductions in data quality or increased risk to research participants, according to a new study in ...

The American Society of Clinical Oncology (ASCO) has been notified of a recent safety notice for the drug Jubbonti (denosumab-bbdz) under the Food and Drug Administration’s Risk Evaluation and ...